← All trials
NCT05158335
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Nov 10, 2021
- Primary completion
- Dec 16, 2022
- Completion date
- Feb 3, 2023
- First posted
- Dec 15, 2021
- Last posted
- Dec 15, 2021
- Enrollment
- 80
- Arms / groups
- 3 / —
- Source
- AACT · ingestion pipeline
Sponsors
- MBX BiosciencesLead sponsor
- MBX BiosciencesStudy director
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.